Asset
Elegrobart
Viridian Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06812325 | phase3 | active_not_recruiting | 2025-02-03 | 2026-04-22 | Viridian Therapeutics, Inc. | A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) |
| NCT07155668 | phase3 | completed | 2025-07-01 | 2026-05-28 | Viridian Therapeutics, Inc. | A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) |
| NCT06625411 | phase3 | active_not_recruiting | 2024-08-27 | 2026-02-12 | Viridian Therapeutics, Inc. | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) |
| NCT06625398 | phase3 | active_not_recruiting | 2024-08-27 | 2026-03-04 | Viridian Therapeutics, Inc. | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) |
FDA applications (0)
This company has no applications containing this asset.